title: Mantle cell lymphoma: an update on management.
abstract: Although response rates are increased, the addition of rituximab to induction chemotherapy has not yet been proven to extend the progression-free and overall survival benefits of chemotherapy alone. In first remission, high-dose therapy plus stem cell rescue improves time to treatment failure and progression-free survival when compared with maintenance interferon alpha. However, relapse rate does not reach a plateau. Radioimmunotherapy has substantial single-agent activity and when combined with chemotherapy may provide a platform onto which rituximab or autologous stem cell transplantation can be added. Targeted therapies are also showing promise and may have a role in maintenance and/or initial therapy.
authors.affiliation: Division of Hematologic Oncology, Memorial-Sloan Kettering Cancer Center, New York, NY 10021, USA. A-Zelenetz@ski.mskcc.org
authors.forename: A D
authors.initials: AD
authors.lastname: Zelenetz
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000628:therapy*; D016499:Radioimmunotherapy; D033581:Stem Cell Transplantation